5月9日盘中，港股荣昌生物（09995.HK）股价出现大幅下跌，跌幅高达5.03%，引发市场关注。截至盘中11时08分，该股报36.850港元。
导致股价下跌的主要原因可能与公司最近公布的2024年度财报有关。根据4月28日披露的年报，荣昌生物2024年度净亏损达14.68亿元，虽然较上年同期15.11亿元的亏损略有收窄，但仍然处于巨额亏损状态。此外，公司2024年加权平均净资产收益率为-53.41%，较上年同期下降了17.81个百分点，反映出公司盈利能力的持续恶化。
尽管荣昌生物2024年实现营业总收入18.15亿元，同比增长52.97%，但巨额亏损可能引发投资者对公司财务状况和未来发展前景的担忧，从而导致股价大幅下跌。市场将继续关注荣昌生物的后续经营表现和扭亏为盈的能力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.